알부민 시장 규모, 점유율, 동향 및 예측 : 제품별, 용도별, 최종 사용자별, 지역별(2026-2034년)

The global albumin market size reached USD 6.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 10.6 Billion by 2034, exhibiting a growth rate (CAGR) of 5.0% during 2026-2034. North America currently dominates the market, holding a significant share of 38.1% in the market. The market is driven by the rising prevalence of chronic conditions such as liver disorders and nephrotic syndrome, which necessitate albumin-based therapies in critical care. Advancements in recombinant production technologies are enabling scalable, plasma-independent solutions to meet growing demand across therapeutic and pharmaceutical applications. Increasing investments in diagnosis, treatment, and biopharmaceutical research in the North American region, particularly in countries like United States and Canada, are reinforcing regional dominance, further augmenting the global albumin market share.

Albumin is a protein produced primarily by the liver and plays a vital role in various physiological functions. It is the most abundant protein in human blood plasma and serves to regulate blood volume by maintaining the osmotic pressure. Albumin also acts as a carrier molecule for substances such as hormones, fatty acids, and medications, aiding in their transport throughout the body. A key function of albumin is to help prevent fluid leakage from blood vessels, thus ensuring that essential fluids remain within the circulatory system. Abnormal levels of albumin in the blood can be indicative of various health conditions. Low levels may point to liver or kidney disorders, malnutrition, or chronic illness, while elevated levels are generally less common and could be indicative of dehydration or severe infection. Hence, the measurement of albumin levels is often included in blood tests as part of routine medical assessments.

The increasing number of surgical procedures majorly drives the global market. Albumin is commonly used in operations to treat hypovolemia, a condition where there is a decrease in the volume of blood plasma. As the global population continues to age and as surgical techniques continue to advance, the number of surgeries being performed is increasing. This trend directly correlates with an uptick in the demand for albumin, thereby driving market growth. Another significant factor contributing to market growth is the expansion of the albumin industry into emerging markets. Developing countries present an untapped market with increasing healthcare spending and improving healthcare infrastructure. As healthcare systems in these countries advance, the demand for high-quality medical supplies, including albumin, rises. In addition, the accelerating awareness about the importance of early diagnosis and treatment of conditions that require albumin is another factor driving the market. Moreover, the influx of both private and public investment in healthcare is creating a positive market outlook.

Albumin Market Trends/Drivers:

Rising Incidence of Chronic Diseases

One of the most significant market drivers for the albumin industry is the rising incidence of chronic diseases such as liver cirrhosis, kidney disorders, and diabetes. These conditions often result in abnormal albumin levels, necessitating regular monitoring and possible supplementation. In addition, the escalating prevalence of these chronic diseases is linked to an aging population, poor dietary habits, and lifestyle factors like lack of exercise and high stress levels. In confluence with this, the growing patient pool demands an increasing supply of albumin products for both diagnostic and therapeutic purposes. The escalating need for albumin in treating these diseases is thereby propelling growth in the industry. Hospitals and clinics are intensifying their reliance on albumin-based tests and treatments, thereby increasing demand and driving market growth.

Advances in Biotechnology and Pharmaceutical Research

Technological advancements in biotechnology and pharmaceutical research have also proven to be a major driver for the albumin industry. These advances have facilitated improved methods of isolating, purifying, and producing albumin on a large scale, thereby making it more accessible and cost-effective. Additionally, innovative techniques in recombinant DNA technology have opened new avenues for albumin applications, including its use as a drug delivery agent for targeted therapies. Additionally, progress in research has paved the way for albumin's use in novel applications such as wound healing and tissue regeneration. The ongoing investments in research and development activities indicate a promising trajectory for the albumin industry, contributing to its expansion.

Regulatory Support and Approvals

Governmental regulations and guidelines play a crucial role in driving the albumin market. Regulatory bodies provide guidelines for the safe production, quality control, and distribution of albumin products. In confluence with this, the presence of such standardizations not only builds consumer trust but also encourages pharmaceutical companies to invest in high-quality products. Timely approvals for new albumin-based products or therapies can substantially accelerate market penetration, thereby acting as a driver for the industry. Moreover, the global harmonization of these guidelines ensures a streamlined and efficient supply chain, facilitating faster time-to-market for new and innovative albumin-based products.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product, application, and end user.

Breakup by Product:

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Human serum albumin dominates the market

The market for human serum albumin products within the albumin industry is experiencing robust growth, propelled by multiple market drivers. A key influencer is the escalating prevalence of chronic liver and kidney diseases that necessitate regular monitoring and treatment of albumin levels. The rising number of surgical procedures, where human serum albumin is used to manage fluid balance, further fuels demand. Advances in biotechnological methods have made it easier to produce and purify human serum albumin, thereby making the product more cost-effective and accessible. This has led to its increased utilization in a range of medical and non-medical applications, such as drug formulation and vaccine stabilization. Additionally, the industry benefits from the regulatory support of agencies like the FDA and EMA, which ensures the quality and safety of these products, building consumer trust. Investment in healthcare from both public and private sectors also aids in market expansion, supporting research and development activities for innovative applications of human serum albumin. These factors collectively serve to drive the market for human serum albumin products.

Breakup by Application:

• Therapeutics
• Drug Formulation and Vaccine
• Component of Media
• Others

Therapeutics holds the largest share in the market

The therapeutics application segment in the albumin industry is witnessing significant growth, driven by multiple converging factors. Foremost among these is the increasing prevalence of chronic conditions like liver disease, kidney disorders, and diabetes, which necessitate the use of albumin-based treatments to regulate blood volume and protein levels. The rising number of surgical procedures, especially in an aging global population, also contributes to elevated demand for albumin as it is commonly used to manage fluid balance during surgeries. Advances in biotechnological research have led to the development of specialized albumin formulations optimized for drug delivery systems, thereby expanding its therapeutic applications. Regulatory bodies like the FDA and EMA have facilitated market growth by setting stringent quality control measures, thereby ensuring the efficacy and safety of albumin products used in therapeutics. Investments from private and public sectors in healthcare infrastructure and research also provide a conducive environment for the expansion of albumin's therapeutic applications. These driving factors combine to propel the market growth of the therapeutics application in the albumin industry.

Breakup by End User:

• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Hospitals and clinics dominate the market

The hospital and clinics segment is a major end-user in the albumin industry, and its market growth is fueled by several influential drivers. First and foremost, the rise in the incidence of chronic diseases like liver and kidney disorders requires consistent monitoring and treatment, often involving albumin-based products. This creates a steady demand for albumin in hospital settings for both diagnostic and therapeutic applications. Furthermore, the increasing number of surgical procedures that utilize albumin for fluid management further escalates demand within hospitals and clinics. Advances in healthcare infrastructure, supported by both public and private investment, have led to an uptick in the adoption of albumin products, as these settings aim for better patient outcomes and quality of care. Regulatory support, in the form of guidelines from bodies like the FDA and EMA, assures the quality of albumin products, thereby building trust and facilitating their usage in hospital settings. Collectively, these factors make hospitals and clinics a pivotal end-user segment, driving demand and, consequently, market growth for the albumin industry.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest albumin market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest segment.

The albumin industry in North America is experiencing significant growth, driven by a variety of factors that create a strong demand for albumin products. One major driver is the high prevalence of chronic conditions like liver diseases, kidney disorders, and diabetes in the region, necessitating frequent monitoring and intervention involving albumin. Additionally, North America has a well-developed healthcare infrastructure with a substantial number of surgical procedures taking place annually, thereby increasing the usage of albumin for surgical and critical care. Technological advancements in biopharmaceuticals, supported by considerable R&D investment, have also contributed to diversifying albumin applications, further driving the market. Regulatory support from agencies such as the FDA assures product quality and safety, enhancing consumer trust. Furthermore, public and private investments in healthcare have been strong, resulting in more hospitals, clinics, and healthcare facilities that use albumin products. These factors, along with a generally aging population that requires more healthcare services, collectively serve to propel the market growth for the albumin industry in North America.

Competitive Landscape:

The global market is experiencing significant growth due to the new albumin formulations and applications. Innovation in this area can lead to more effective and versatile albumin products, opening new markets and therapeutic avenues. Along with this, companies are expanding into emerging markets where there is rising healthcare spending and an increasing patient pool. This diversification helps mitigate risks associated with dependence on mature markets. In addition, the escalating strategic partnerships with other healthcare companies, research institutions, and even governmental bodies help in sharing knowledge, costs, and distribution networks. Therefore, this is significantly supporting the market. With regulatory bodies emphasizing the safety and efficacy of medical products, companies in the albumin market are focusing on quality control to adhere to these guidelines, further impacting the market. In addition, brands are adopting advanced logistics and inventory management systems to ensure timely delivery, which is acting as another growth-inducing factor. Furthermore, product differentiation by offering albumin products that serve specific niches within healthcare is contributing to the market.

The market report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.

Some of the key players in the market include:

• Albumedix Ltd.
• Biotest AG
• Celgene Corporation (Bristol-Myers Squibb Company)
• CSL Limited
• Grifols SA
• HiMedia Laboratories
• Medxbio Pte Ltd.
• Merck KGaA
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Ventria Bioscience Inc.

Key Questions Answered in This Report

• What was the size of the global albumin market in 2025?
• What is the expected growth rate of the global albumin market during 2026-2034?
• What are the key factors driving the global albumin market?
• What has been the impact of COVID-19 on the global albumin market?
• What is the breakup of the global albumin market based on the product?
• What is the breakup of the global albumin market based on the application?
• What is the breakup of the global albumin market based on end user?
• What are the key regions in the global albumin market?
• Who are the key players/companies in the global albumin market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Albumin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Human Serum Albumin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Bovine Serum Albumin
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Recombinant Albumin
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Therapeutics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Drug Formulation and Vaccine
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Component of Media
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pharmaceutical and Biotechnology Companies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Research Institutes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Albumedix Ltd
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Biotest AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Celgene Corporation (Bristol-Myers Squibb Company)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 CSL Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Grifols SA
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 HiMedia Laboratories
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Medxbio Pte Ltd
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Merck KGaA
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Octapharma AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis
  • 14.3.10 Takeda Pharmaceutical Company Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Ventria Bioscience Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio